Enfermedad invasiva meningocócica en uruguay. Informe epidemiológico y recomendaciones, mayo 2002

[1]  G. Peter.  Update on meningococcal vaccine. , 2001, The Pediatric infectious disease journal.

[2]  H. Peltola.  Prophylaxis of bacterial meningitis. , 1999, Infectious disease clinics of North America.

[3]  M. Hibberd,et al.  Cellular Immune Responses to Neisseria meningitidis in Children , 1999, Infection and Immunity.

[4]  J. Tappero,et al.  Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. , 1999, JAMA.

[5]  J. Wenger.  Serogroup B meningococcal disease: new outbreaks, new strategies. , 1999, JAMA.

[6]  D. Fleming,et al.  Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. , 1999, JAMA.

[7]  B. Plikaytis,et al.  Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. , 1998, The Journal of infectious diseases.

[8]  C. H. Klein,et al.  Avaliação da proteção conferida pela vacina antimeningocócica BC no Estado de Santa Catarina, Brazil, 1990/92 , 1996 .

[9]  M. Halloran,et al.  Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. , 1995, International journal of epidemiology.

[10]  C. Sacchi,et al.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil , 1992, The Lancet.

[11]  M. H. Terry,et al.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. , 1991, NIPH annals.

[12]  J. Stuart,et al.  AN OUTBREAK OF MENINGOCOCCAL DISEASE IN GLOUCESTERSHIRE , 1986, The Lancet.